AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11477347 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus+MMF
Number of subjects: 223
Study 11477347 — intervention group
Group type: COMPARATOR
Intervention: CsA+MMF
Number of subjects: 223
Study 11477347 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus+AZA
Number of subjects: 223
Study 9570244 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with metronidazole (500 mg twice daily for 2 weeks), amoxycillin (500 mg three times daily for 2 weeks), and omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 60
Study 9570244 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with amoxycillin (500 mg three times daily for 2 weeks) and omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 60
Study 9570244 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 60
Study 9570244 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 60
Study 7978442 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 0 micrograms.kg‐1.min‐1
Number of subjects: 47
Study 7978442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 1 micrograms.kg‐1.min‐1
Number of subjects: 47
Study 7978442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2 micrograms.kg‐1.min‐1
Number of subjects: 47
Study 7978442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 3 micrograms.kg‐1.min‐1
Number of subjects: 47
Study 2659003 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl magnesium glutamate (NAAGA)
Number of subjects: 20
Study 2659003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30325764 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART for 48 weeks
Number of subjects: 82
Study 30325764 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 82
Study 28581818 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg a.m. and placebo p.m. (n=8)
Number of subjects: 16
Study 28581818 — intervention group
Group type: COMPARATOR
Intervention: metformin 500 mg bid (n=8)
Number of subjects: 16
Study 25462650 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance-related addictions (alcohol, tobacco, marijuana, cocaine)
Number of subjects: 4000
Study 25462650 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral addictions (problematic gambling, eating, shopping, sexual behavior, video gaming, work)
Number of subjects: 4000
Study 25462650 — intervention group
Group type: EXPERIMENTAL
Intervention: General public perceptions
Number of subjects: 4000
Study 24115597 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated localization of the ascending aorta (AAo) and descending aorta (DAo) using phase contrast MRI.
Number of subjects: 1884
Study 24115597 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated flow volume measurement for AAo and DAo.
Number of subjects: 1884
Study 22840621 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 20
Study 22840621 — intervention group
Group type: COMPARATOR
Intervention: Non‐invasive sham acupuncture
Number of subjects: 20
Study 19419254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 0
Study 19419254 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0
Study 19419254 — intervention group
Group type: COMPARATOR
Intervention: Clevidipine-nitroglycerin
Number of subjects: 0
Study 17907081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 17907081 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-analoga and antiandrogens
Number of subjects: 0
Study 17907081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0
Study 17907081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytostatic therapy
Number of subjects: 0
Study 15198380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin, 1 mg daily for 7 days, and 5 mg on the eighth day
Number of subjects: 20
Study 15198380 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection daily for 8 days
Number of subjects: 20
Study 11740975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation challenge test (30 breaths/min for 4 min)
Number of subjects: 125
Study 9554677 — intervention group
Group type: EXPERIMENTAL
Intervention: IVAC 4200 BP performed by trained investigators (research automated [RA])
Number of subjects: 145
Study 9554677 — intervention group
Group type: EXPERIMENTAL
Intervention: IVAC 4200 BP performed by ward personnel (ward automated [WA])
Number of subjects: 145
Study 9554677 — intervention group
Group type: COMPARATOR
Intervention: Mercury manometer (MM)
Number of subjects: 145
Study 8300656 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reamed locked nailing
Number of subjects: 29
Study 8300656 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 29
Study 2499825 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin (PHT)
Number of subjects: 20
Study 2499825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 31169373 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative images in the background during repeated displays
Number of subjects: 0
Study 31169373 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive images in the background during repeated displays
Number of subjects: 0
Study 31169373 — intervention group
Group type: COMPARATOR
Intervention: Neutral images in the background during repeated displays
Number of subjects: 0
Study 31169373 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of affective background images in Phase 2
Number of subjects: 0
Study 29774521 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN + BTZ + DEX
Number of subjects: 147
Study 29774521 — intervention group
Group type: COMPARATOR
Intervention: Placebo + BTZ + DEX
Number of subjects: 147
Study 28646924 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-level prophylaxis with single-dose ciprofloxacin
Number of subjects: 400
Study 28646924 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-wide prophylaxis with single-dose ciprofloxacin
Number of subjects: 400
Study 28646924 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study 26369640 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Gy single dose
Number of subjects: 112
Study 26369640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 Gy single dose
Number of subjects: 112
Study 23351188 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 (100 mg once daily for 3 days)
Number of subjects: 120
Study 23351188 — intervention group
Group type: COMPARATOR
Intervention: Control (no neuroprotective agents)
Number of subjects: 120
Study 20937617 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µL of the essential oil
Number of subjects: 36
Study 20937617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20003436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg per os daily
Number of subjects: 80
Study 20003436 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta-1b every other day
Number of subjects: 80
Study 17261601 — intervention group
Group type: EXPERIMENTAL
Intervention: LT vaccine patch (50 microg) administered on days 0 and 21
Number of subjects: 60
Study 17261601 — intervention group
Group type: COMPARATOR
Intervention: Oral ETEC challenge (LT+ ST+ E2447A)
Number of subjects: 60
Study 17261601 — intervention group
Group type: COMPARATOR
Intervention: Oral cholera toxin B subunit-containing cholera vaccine
Number of subjects: 60
Study 15059332 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting alone (Group A, n = 27)
Number of subjects: 53
Study 15059332 — intervention group
Group type: COMPARATOR
Intervention: Stenting followed by radiotherapy and/or chemotherapy (Group B, n = 26)
Number of subjects: 53
Study 15059332 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting followed by radiotherapy and/or chemotherapy (Group B)
Number of subjects: 53
Study 11224828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 2 mg/kg/dose twice daily for 5 days
Number of subjects: 695
Study 11224828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 695
Study 11224828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 8968633 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy with ritual prevention
Number of subjects: 46
Study 2302538 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-up or toe-down tilts of a platform (perturbations stretching the soleus muscle)
Number of subjects: 0
Study 2302538 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-up or toe-down tilts of a platform (perturbations stretching the tibialis anterior muscle)
Number of subjects: 0
Study 2302538 — intervention group
Group type: COMPARATOR
Intervention: Standing and holding onto a frame
Number of subjects: 0
Study 2302538 — intervention group
Group type: COMPARATOR
Intervention: Translations (forward and backward) stretching the same leg muscle
Number of subjects: 0
Study 6776577 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 0
Study 6776577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alcohol + tobacco (4 cigarettes + 0.65 g/kg ethyl alcohol)
Number of subjects: 0
Study 6776577 — intervention group
Group type: COMPARATOR
Intervention: Tobacco (4 cigarettes)
Number of subjects: 0
Study 6776577 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 0
Study 6776577 — intervention group
Group type: COMPARATOR
Intervention: Combined alcohol + tobacco
Number of subjects: 0
Study 31262292 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Number of subjects: 0
Study 27924388 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic simulator
Number of subjects: 40
Study 27924388 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simulator
Number of subjects: 40
Study 24408084 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS >12)
Number of subjects: 2627
Study 24408084 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS = 7-12)
Number of subjects: 2627
Study 24408084 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS <7)
Number of subjects: 2627
Study 24408084 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS >32)
Number of subjects: 2627
Study 24408084 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS = 23-32)
Number of subjects: 2627
Study 24408084 — intervention group
Group type: COMPARATOR
Intervention: SYNTAX score tertile (SS <22)
Number of subjects: 2627
Study 25310749 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 100
Study 25310749 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet education
Number of subjects: 100
Study 22748849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin-based biological adhesive applied to the suture line
Number of subjects: 104
Study 22748849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adhesive applied)
Number of subjects: 104
Study 20467943 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/RTV)
Number of subjects: 599
Study 20467943 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/RTV)
Number of subjects: 599
Study 17594297 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected distraction
Number of subjects: 32
Study 17594297 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 16179043 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (20 microg.kg(‐1)) + Remifentanil (1 microg.kg(‐1) bolus followed by 0.25 microg.kg(‐1).min(‐1) for 10 min, then 0.5 microg.kg(‐1).min(‐1) for 10 min)
Number of subjects: 40
Study 16179043 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (1 microg.kg(‐1) bolus followed by 0.25 microg.kg(‐1).min(‐1) for 10 min, then 0.5 microg.kg(‐1).min(‐1) for 10 min)
Number of subjects: 40
Study 12240783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 894
Study 12240783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 894
Study 10404769 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (2 mg micronised oestradiol daily)
Number of subjects: 60
Study 10404769 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + P (sequentially combined with a progestagen on 14 days of each cycle)
Number of subjects: 60
Study 10404769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8803649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (up to 150 mg/day as a single bedtime dose)
Number of subjects: 150
Study 8803649 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (240 mg/day on a twice‐daily schedule)
Number of subjects: 150
Study 8803649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8803649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 150
Study 8803649 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 150
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon (150 micrograms desogestrel + 30 micrograms ethinyloestradiol)
Number of subjects: 0
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercilon (150 micrograms desogestrel + 20 micrograms ethinyloestradiol)
Number of subjects: 0
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon (150 micrograms levonorgestrel + 30 micrograms ethinyloestradiol)
Number of subjects: 0
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel OCs (Marvelon and Mercilon)
Number of subjects: 0
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon
Number of subjects: 0
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: All OCs
Number of subjects: 0
Study 1535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon and Mercilon
Number of subjects: 0
Study 6705695 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-cavity radical operation
Number of subjects: 54
Study 6705695 — intervention group
Group type: COMPARATOR
Intervention: Blunt oesophagectomy without thoracotomy
Number of subjects: 54
Study 6705695 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 54
Study 6705695 — intervention group
Group type: COMPARATOR
Intervention: No postoperative radiotherapy
Number of subjects: 54
Study 30499157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 42
Study 30499157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 42
Study 30499157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28952887 — intervention group
Group type: EXPERIMENTAL
Intervention: Early outpatient palliative care consultations
Number of subjects: 142
Study 28952887 — intervention group
Group type: COMPARATOR
Intervention: Delayed outpatient palliative care consultations
Number of subjects: 142
Study 27153823 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen with ribavirin (N = 615)
Number of subjects: 1690
Study 27153823 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen
Number of subjects: 1690
Study 24668660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg for normal/mildly impaired renal function
Number of subjects: 161
Study 24668660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg for moderate renal impairment
Number of subjects: 161
Study 24668660 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (control)
Number of subjects: 161
Study 22229758 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + CM reinforcing submission of negative samples with $250 in prizes ($250Abs)
Number of subjects: 442
Study 22229758 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + CM reinforcing attendance ($250Att)
Number of subjects: 442
Study 22229758 — intervention group
Group type: EXPERIMENTAL
Intervention: $560Abs (higher magnitude CM for initially cocaine-positive patients)
Number of subjects: 442
Study 22229758 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 442
Study 21125739 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish adaptation of the Visual Function Questionnaire (VFQ-25)
Number of subjects: 108
Study 17989110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing
Number of subjects: 206
Study 17989110 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing
Number of subjects: 206
Study 17989110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing (wild-type patients)
Number of subjects: 206
Study 17989110 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (wild-type patients)
Number of subjects: 206
Study 17989110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing (multiple variant carriers)
Number of subjects: 206
Study 17989110 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (multiple variant carriers)
Number of subjects: 206
Study 16301267 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve blockade (CFNB) with bupivacaine 0.2% (median infusion rate 9.3 mL/h)
Number of subjects: 108
Study 16301267 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia (CEA) with ropivacaine 0.2% and fentanyl 4 microg/mL (median infusion rate 7.6 mL/h)
Number of subjects: 108
Study 16301267 — intervention group
Group type: EXPERIMENTAL
Intervention: CFNB group
Number of subjects: 108
Study 16301267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 11973207 — intervention group
Group type: EXPERIMENTAL
Intervention: Core temperature of 34 degrees C (mild hypothermia)
Number of subjects: 40
Study 11973207 — intervention group
Group type: COMPARATOR
Intervention: Core temperature of 37 degrees C (normothermia)
Number of subjects: 40
Study 9803099 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate (Sorbsan)
Number of subjects: 50
Study 9803099 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze/cotton gauze roll
Number of subjects: 50
Study 8572630 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV (Mitomycin C, Methotrexate, Vincristine)
Number of subjects: 108
Study 8572630 — intervention group
Group type: EXPERIMENTAL
Intervention: MMVM (MMV + Medroxyprogesterone Acetate)
Number of subjects: 108
Study 8572630 — intervention group
Group type: EXPERIMENTAL
Intervention: MMVP (MMV + Prednisolone)
Number of subjects: 108
Study 2360833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 8
Study 391342 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (tricyclic antidepressant; mean dose 106 mg at night)
Number of subjects: 135
Study 391342 — intervention group
Group type: COMPARATOR
Intervention: Monoamine oxidase inhibitors (MAOIs; phenelzine mean dose 45 mg/day, isocarboxazid mean dose 32 mg/day)
Number of subjects: 135
Study 391342 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (phenelzine plus trimipramine or isocarboxazid plus trimipramine)
Number of subjects: 135
Study 31964186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19
Study 31964186 — intervention group
Group type: COMPARATOR
Intervention: Moderate continuous training (MCT)
Number of subjects: 19
Study 30282088 — intervention group
Group type: COMPARATOR
Intervention: Tissue-level implants restored by platform matching (control)
Number of subjects: 35
Study 30282088 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-level implants restored by platform switching (test)
Number of subjects: 35
Study 30282088 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 35
Study 28957381 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment tracking and community outreach systems
Number of subjects: 3149
Study 28957381 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 3149
Study 26576815 — intervention group
Group type: EXPERIMENTAL
Intervention: Klar bleiben intervention
Number of subjects: 3000
Study 23442203 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game-based learning method
Number of subjects: 0
Study 23442203 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning method
Number of subjects: 0
Study 21521913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoionomer
Number of subjects: 30
Study 21521913 — intervention group
Group type: COMPARATOR
Intervention: Resin‐modified glass ionomer
Number of subjects: 30
Study 21521913 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer cement
Number of subjects: 30
Study 20302221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acetyl‐salicylic acid (ASA)
Number of subjects: 33
Study 20302221 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoprofen (KTP)
Number of subjects: 33
Study 20302221 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 20302221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ketoprofen (KTP)
Number of subjects: 33
Study 16928616 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary podocyte mRNA excretion
Number of subjects: 15
Study 16928616 — intervention group
Group type: EXPERIMENTAL
Intervention: High synaptopodin mRNA levels
Number of subjects: 15
Study 16928616 — intervention group
Group type: EXPERIMENTAL
Intervention: High nephrin mRNA levels
Number of subjects: 15
Study 16928616 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal blood pressure, urinalysis, and serum creatinine concentration
Number of subjects: 15
Study 14769712 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone, 200 mg/d
Number of subjects: 146
Study 14769712 — intervention group
Group type: COMPARATOR
Intervention: Propafenone, 450 mg/d
Number of subjects: 146
Study 11379374 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic conjugated estrogen tablets
Number of subjects: 120
Study 11379374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9135227 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (7.5 mg dissolved in 250 ml saline solution)
Number of subjects: 20